Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: MRS Commun. 2017 Sep 12;7(3):442–449. doi: 10.1557/mrc.2017.85

Figure 1.

Figure 1

Biomaterial platforms allow us to recreate tumor tissues into hydrogel-based biochips to examine patient-specific responses to a range of therapeutic strategies. (a) Glioblastoma microenvironment transitions in hyaluronic acid content can be recreated into a (b) gelatin-HA gradient hydrogel by using a microfluidic device. (c) Response to erlotinib tyrosine kinase inhibitor is analyzed in the gradient platforms.